Pharmaceuticals Malaysia

Malaysia KRAS Inhibitors Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Malaysia KRAS Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.1 Mn Placeholder estimate
Estimate 2025 $1.5 Mn 0.1% of the global market
Projected 2034 $21.9 Mn 1,399.3% Adds $20.4 Mn over 9 forecast years
CAGR 2025–2034 35.1% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • Malaysia is 0.13% of the global market.
  • In APAC, the largest is China at $93.6 Mn.
  • Fastest growing: India at 37.7% a year.
  • Malaysia ranks 8th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$20.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
KRAS Inhibitors Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.1 Mn — —
2025 (base) $1.5 Mn +$0.4 Mn —
2026 (forecast) $2.0 Mn +$0.5 Mn +35.1%
2027 (forecast) $2.7 Mn +$0.7 Mn +82.5%
2028 (forecast) $3.6 Mn +$0.9 Mn +146.6%
2029 (forecast) $4.9 Mn +$1.3 Mn +233.1%
2030 (forecast) $6.6 Mn +$1.7 Mn +350.1%
2031 (forecast) $8.9 Mn +$2.3 Mn +508%
2032 (forecast) $12.0 Mn +$3.1 Mn +721.5%
2033 (forecast) $16.2 Mn +$4.2 Mn +1,009.8%
2034 (forecast) $21.9 Mn +$5.7 Mn +1,399.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Malaysia KRAS Inhibitors Market Analysis at a glance
Market size, 2025$1.5 Mn placeholder estimate
Forecast, 2034$21.9 Mn placeholder estimate
Growth (CAGR), 2025–203435.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersAmgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines, Novartis AG (see all)
Regulator in MalaysiaNPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials11 in MalaysiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Malaysia KRAS Inhibitors Market Analysis Executive Summary

KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.

Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).

Bar chart: Malaysia KRAS Inhibitors market size, 2024–2034, placeholder estimates. $1.1 Mn in 2024, $1.5 Mn in 2025 and $21.9 Mn in 2034, 35.1% CAGR.
Malaysia KRAS Inhibitors market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Malaysia KRAS Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for KRAS Inhibitors Market in Malaysia

The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for KRAS Inhibitors Market in Malaysia

KRAS Inhibitors in Malaysia: rules, payment and research

Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).⁠[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.⁠[2] ClinicalTrials.gov lists 11 studies on KRAS Inhibitors that are recruiting, active or about to start in Malaysia.⁠[3]

[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[2] Ministry of Health Malaysia. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in KRAS Inhibitors right now, from free public sources.

Clinical trials

11 active trials in Malaysia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Revolution Medicines 15 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Merck & Co., Inc. 10 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Verastem, Inc. 10 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Mirati Therapeutics Inc. 8 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Roche 8 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

KRAS Inhibitors in context

Malaysia compared

  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 8.0% of people (2025). World: 10.4% of people (2025). 8th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the KRAS Inhibitors market in Malaysia?
Placeholder estimate: about $1.5 Mn in 2025, rising to about $21.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the KRAS Inhibitors market in Malaysia growing?
Placeholder estimate: about 35.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the KRAS Inhibitors market report cover?
The report splits the market by target (KRAS G12C, KRAS G12D, Pan-KRAS), indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the KRAS Inhibitors market?
Key players include Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines and Novartis AG.
What is driving the KRAS Inhibitors market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.
Who regulates KRAS Inhibitors in Malaysia?
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA). Source: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in Malaysia?
Public clinics and hospitals run by the Ministry of Health give heavily subsidised care. Source: Ministry of Health Malaysia. Checked 14 Nov 2026.
How many clinical trials on KRAS Inhibitors are running in Malaysia?
11 studies are recruiting, active or about to start in Malaysia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.
How much research is published on KRAS Inhibitors?
PubMed lists 440 papers on KRAS Inhibitors added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Malaysia

See all

Related on oncology

See the topic